[{"id":"b3fcd5d4-2376-4a44-a782-f5af77183569","acronym":"LEAHRN","url":"https://clinicaltrials.gov/study/NCT02724579","created_at":"2021-01-18T13:20:08.012Z","updated_at":"2025-02-25T15:10:23.410Z","phase":"Phase 2","brief_title":"Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","source_id_and_acronym":"NCT02724579 - LEAHRN","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["MYCN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 11/17/2017","start_date":" 11/17/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-13"},{"id":"0340b14e-a127-4e74-868c-fbd3285909ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05761951","created_at":"2023-03-09T15:01:38.080Z","updated_at":"2025-02-25T16:18:37.564Z","phase":"Phase 2","brief_title":"Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT05761951","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CTNNB1 • AXIN1 • RSPO2 • ZNRF3","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • AXIN1 • RSPO2 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sirexatamab (DKN-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/29/2023","start_date":" 08/29/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2029","study_completion_date":" 01/31/2029","last_update_posted":"2024-11-18"},{"id":"a47ddf13-3816-49fc-80b2-c615e6b61c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03264664","created_at":"2023-11-04T04:12:31.080Z","updated_at":"2024-07-02T16:34:27.421Z","phase":"Phase 1","brief_title":"Study of E7386 in Participants With Selected Advanced Neoplasms","source_id_and_acronym":"NCT03264664","lead_sponsor":"Eisai Inc.","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-11"},{"id":"8326d952-c482-49fa-825b-eb6a21c8a525","acronym":"ALTITUDES","url":"https://clinicaltrials.gov/study/NCT02867033","created_at":"2021-01-18T14:04:27.919Z","updated_at":"2024-07-02T16:35:00.172Z","phase":"","brief_title":"National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)","source_id_and_acronym":"NCT02867033 - ALTITUDES","lead_sponsor":"Centre Oscar Lambret","biomarkers":" CTNNB1 • APC","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 628","initiation":"Initiation: 03/22/2016","start_date":" 03/22/2016","primary_txt":" Primary completion: 11/01/2030","primary_completion_date":" 11/01/2030","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-05-30"},{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"ca6866f9-37af-4ed6-b384-0ce5df98af8a","acronym":"NCI-2018-01284","url":"https://clinicaltrials.gov/study/NCT03008408","created_at":"2021-01-18T14:48:06.189Z","updated_at":"2024-07-02T16:35:11.704Z","phase":"Phase 2","brief_title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT03008408 - NCI-2018-01284","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 08/31/2028","primary_completion_date":" 08/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-04-03"},{"id":"d1c8d534-b991-4bdd-aee5-250c8074853d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03833700","created_at":"2023-07-12T22:09:04.322Z","updated_at":"2024-07-02T16:35:16.167Z","phase":"Phase 1","brief_title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","source_id_and_acronym":"NCT03833700","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" RNF43 • APC • AXIN1 • ZNRF3","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation","tags":["RNF43 • APC • AXIN1 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-06"},{"id":"4c415dce-6421-46bd-97fd-5cc700ebf780","acronym":"","url":"https://clinicaltrials.gov/study/NCT05797805","created_at":"2023-04-04T16:04:03.714Z","updated_at":"2024-07-02T16:35:18.401Z","phase":"Phase 1/2","brief_title":"A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05797805","lead_sponsor":"Iterion Therapeutics","biomarkers":" AXIN1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/13/2023","start_date":" 09/13/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-21"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"c05e0fd8-f927-4e8c-a832-08281974edc0","acronym":"ABRADES","url":"https://clinicaltrials.gov/study/NCT03275818","created_at":"2021-01-18T16:10:41.239Z","updated_at":"2024-07-02T16:36:09.269Z","phase":"Phase 2","brief_title":"Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT03275818 - ABRADES","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" CTNNB1 • SPARC","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 05/09/2017","start_date":" 05/09/2017","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-06-07"},{"id":"cc53a890-89ed-4959-a512-acb62dcd9222","acronym":"HELP-2020","url":"https://clinicaltrials.gov/study/NCT04506398","created_at":"2021-06-24T18:52:50.426Z","updated_at":"2024-07-02T16:36:28.684Z","phase":"","brief_title":"Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence","source_id_and_acronym":"NCT04506398 - HELP-2020","lead_sponsor":"RenJi Hospital","biomarkers":" TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3","pipe":" | ","alterations":" CTNNB1 mutation • TERT mutation • TERT promoter mutation","tags":["TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation • TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/10/2020","start_date":" 09/10/2020","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-06-24"},{"id":"8e96cc7a-6dec-4aa5-96fd-2012bb5fe9bb","acronym":"LUDOC","url":"https://clinicaltrials.gov/study/NCT02062697","created_at":"2021-01-18T09:30:05.355Z","updated_at":"2024-07-02T16:36:49.646Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","source_id_and_acronym":"NCT02062697 - LUDOC","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-25"}]